Novyra Pharmachem Limited has announced a key leadership appointment following its board meeting held on February 6, 2026. The company, formerly known as Bansisons Tea Industries Limited, approved the appointment of a new Additional Director during the meeting that concluded at 5:30 p.m.

Board Meeting Outcome

The board meeting, which commenced at 4:30 p.m. on February 6, 2026, resulted in the appointment of Anilkumar Mohanbhai Amreliya (DIN: 11339148) as Additional Director (Executive Director) of the company. The appointment is effective from February 6, 2026, and the director will hold office until the ensuing Annual General Meeting.

Director Profile and Experience

Mr. Amreliya brings extensive business experience to the role, having been engaged in business operations with over 25 years of expertise in sales and marketing. His professional background includes directorships in other companies, specifically Vaidehi Healthcare Private Limited and Vaid Super Specialty Hospital Private Limited.

Regulatory Compliance and Disclosures

The company has made comprehensive disclosures in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key regulatory confirmations include:

• The director does not hold more than 2% voting power in any companies
• He does not hold any shares of the company
• No relationships exist between directors
• The director is not debarred from holding directorial office by SEBI or any other authority

Company Information

Novyra Pharmachem Limited, with CIN L21001GJ1987PLC171085, operates from its registered office located at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, B/h Zenith Mill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat. The appointment reflects the company's ongoing efforts to strengthen its leadership team with experienced professionals in key operational areas.

Bansisons Tea Industries Limited, now operating as Novyra Pharmachem Limited, has announced its unaudited financial results for the third quarter ended December 31, 2025. The company's Board of Directors approved these results during their meeting held on January 26, 2026, at the registered office in Surat, Gujarat.

Financial Performance Overview

The company reported challenging financial performance for the quarter, with no revenue generation from operations. The financial results show a net loss of ₹1.15 lakhs for Q3 FY26, representing a deterioration from the ₹0.88 lakhs loss recorded in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, the company's performance showed mixed results compared to the previous year. While other income increased to ₹6.31 lakhs from nil in the corresponding period last year, total expenses also rose significantly.

Expense Structure and Key Metrics

The company's expense structure for Q3 FY26 comprised employee benefit expenses of ₹0.39 lakhs, depreciation and amortisation expense of ₹0.73 lakhs, and other expenses of ₹0.03 lakhs. The increase in depreciation expenses indicates potential capital investments or asset additions during the period.

Earnings Per Share Performance:

• Basic EPS for Q3 FY26: ₹(0.02)
• Diluted EPS for Q3 FY26: ₹(0.02)
• Nine-month EPS: ₹(0.03)

The company's paid-up equity share capital stands at ₹630.00 lakhs as of December 31, 2025, with a face value of ₹10.00 per share.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee before approval by the Board of Directors. The statutory auditors D G M S & Co., Chartered Accountants, conducted a limited review of the unaudited results. The results have been prepared in accordance with Indian Accounting Standard 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013.

The Board meeting commenced at 5:30 PM and concluded at 7:00 PM on January 26, 2026, with Director Hiren Dhirajlal Shah (DIN: 09842161) signing the results on behalf of the company.